Kaplan-Meier estimate

Kaplan-Meier estimate

(kap'lăn mī'ĕr),
nonparametric method of compiling life tables or survival tables that combines calculated probabilities of survival with estimates to allow for censored (missing) observations; used mainly in survival studies of cancer and similar long-term diseases.

Kap·lan-Mei·er es·ti·mate

(kap'lăn-mī'ĕr es'ti-măt)
Nonparametric method of compiling life tables or survival tables that combines calculated probabilities of survival with estimates to allow for censored (missing) observations; used mainly in survival studies of cancer and similar long-term diseases.
References in periodicals archive ?
The Kaplan-Meier estimate of survival was used to generate survivorship curves for endpoints of revision and component loosening.
The Kaplan-Meier estimate of the survivor function indicates that the median duration of exporting a product to the United States is very short, anywhere between two and four years.
The absolute 5-year risk of nonfatal MI was 5%; the risk for MI or vascular death was 16%; and the risk for recurrent stroke, MI, or vascular death was 25%, according to a Kaplan-Meier estimate of survival.
Most of the patients (61%) had no symptoms at the time of diagnosis, but 62% had symptoms of pruritis or fatigue within 5 years; only 5% had no symptoms after 20 years, according to a Kaplan-Meier estimate (Gastroenterology 123[4]:1044-51, 2002).
The Kaplan-Meier estimate analysis of patients alive at five years show a strong trend in favor of Ceplene + IL-2 (Kaplan-Meier, P=0.
In patients without prior antiangiogenic therapy, progression-free survival at 6 months (PFS6) assessed by Kaplan-Meier estimate was 25%, with a 30% rate of censoring at the time of analysis.
The Kaplan-Meier estimate for continued sustained response over five years for all patients in the study is 97 percent with a 95 percent Confidence Interval of [95 %, 99 %].
Patients with an HCT-CI score of 3 or greater had an overall response rate of 34%, an induction death rate (death within 30 days of first induction) of 14%, and a Kaplan-Meier estimate of survival at twelve months of 21%.
The PROPEL trial database has been locked and the Kaplan-Meier estimate for the median duration of response is 287 days, or 9.
The Kaplan-Meier estimate of median overall survival for patients who responded to Onrigin(TM) was 8.